Two Sigma Investments LP Has $1.02 Million Stake in ProQR Therapeutics (NASDAQ:PRQR)

Two Sigma Investments LP boosted its stake in ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 512.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 383,134 shares of the biopharmaceutical company's stock after buying an additional 320,614 shares during the period. Two Sigma Investments LP owned 0.47% of ProQR Therapeutics worth $1,015,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in ProQR Therapeutics in the 4th quarter worth approximately $30,000. Invesco Ltd. bought a new position in shares of ProQR Therapeutics in the fourth quarter worth $32,000. Alpine Global Management LLC acquired a new position in shares of ProQR Therapeutics during the fourth quarter valued at $39,000. Two Sigma Securities LLC acquired a new stake in ProQR Therapeutics in the fourth quarter worth about $40,000. Finally, ADAR1 Capital Management LLC bought a new position in ProQR Therapeutics in the 4th quarter valued at about $54,000. 32.65% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Evercore ISI assumed coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 price objective for the company. Cantor Fitzgerald initiated coverage on ProQR Therapeutics in a research note on Tuesday, April 29th. They set an "overweight" rating and a $8.00 price target for the company. Citigroup upgraded ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price target on the stock in a research report on Monday, March 10th. HC Wainwright raised their target price on ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Friday, March 14th. Finally, Chardan Capital reissued a "buy" rating and issued a $4.00 price target on shares of ProQR Therapeutics in a report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, ProQR Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $8.00.

ProQR Therapeutics Trading Down 4.2%

NASDAQ PRQR traded down $0.08 on Monday, reaching $1.83. The stock had a trading volume of 257,017 shares, compared to its average volume of 638,080. ProQR Therapeutics has a 1 year low of $1.07 and a 1 year high of $4.62. The business has a 50 day moving average price of $1.51 and a 200 day moving average price of $2.12. The company has a market capitalization of $192.54 million, a price-to-earnings ratio of -5.72 and a beta of 0.31.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. The business had revenue of $4.89 million for the quarter, compared to the consensus estimate of $4.90 million. On average, analysts anticipate that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

ProQR Therapeutics Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).